Invitae Aktie [WKN DE: A14NKG / ISIN: US46185L1035]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Invitae Corp

09.05.18		Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018 (PR Newswire)
07.05.18		Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy (PR Newswire)
03.05.18		Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference (PR Newswire)
27.04.18		Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA) (PR Newswire)
25.04.18		Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018 (PR Newswire)
10.04.18		Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing (PR Newswire)
22.03.18		Invitae expands network of patients in rare and ultra-rare diseases (PR Newswire)
16.03.18		Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information (PR Newswire)
27.02.18		Invitae expands existing credit facility to provide up to $40.0 million in available growth capital (PR Newswire)
26.02.18		Invitae to present at the Cowen and Company 38th Annual Health Care Conference (PR Newswire)
12.02.18		Invitae reports over 150% volume and over 170% revenue growth for 2017 (PR Newswire)
31.01.18		Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference (PR Newswire)
29.01.18		Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018 (PR Newswire)
08.01.18		Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018 (PR Newswire)
05.12.17		Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families (PR Newswire)
15.11.17		Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services (PR Newswire)
13.11.17		FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
06.11.17		Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017 (PR Newswire)
30.10.17		Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage (PR Newswire)
26.10.17		Safeguard Scientifics Announces Third Quarter 2017 Financial Results (PR Newswire)
24.10.17		Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017 (PR Newswire)
17.10.17		Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection (PR Newswire)
05.10.17		Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide (PR Newswire)
13.09.17		Invitae highlighting new research, expanded suite of services at National Society of Genetic Counselors (NSGC) 36th Annual Conference (PR Newswire)
13.09.17		Invitae to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
29.08.17		Invitae to Participate in the Morgan Stanley 15th Annual Global Healthcare Conference (PR Newswire)
28.08.17		LendingClub To Hold 2017 Investor Day (PR Newswire)
07.08.17		Invitae Reports Second Quarter 2017 Results (PR Newswire)
02.08.17		TrackR Closes $50M Dollars In Series B Funding Led By Revolution Growth (PR Newswire)
31.07.17		Safeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae Corporation (PR Newswire)
31.07.17		Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life (PR Newswire)
31.07.17		Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results (PR Newswire)
24.07.17		Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 7, 2017 (PR Newswire)
12.06.17		Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis Platform (PR Newswire)
05.06.17		ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines (PR Newswire)
25.05.17		Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand (PR Newswire)
12.05.17		Invitae to Present at the UBS Global Healthcare Conference (PR Newswire)
08.05.17		Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017 (PR Newswire)
28.04.17		New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing (PR Newswire)
24.04.17		Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017 (PR Newswire)
20.04.17		Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses... (PR Newswire)
03.04.17		Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis (PR Newswire)
30.03.17		Invitae announces introduction of exome testing (PR Newswire)
23.03.17		Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults (PR Newswire)
22.03.17		Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting (PR Newswire)
14.03.17		Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting (PR Newswire)
21.02.17		Invitae to present at the Cowen and Company 37th Annual Health Care Conference (PR Newswire)
17.02.17		New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

DAX 40-Titel Rheinmetall-Aktie: So viel Gewinn hätte ein Investment in Rheinmetall von vor 3 Jahren eingefahren

BASF-Aktie und Co. legen kräftig zu: Chemiesektor atmet auf

ATX legt letztlich kräftig zu -- DAX geht nach neuem Rekordhoch stärker aus dem Handel -- US-Börsen uneins -- Asiens Börsen schließen fester

Ripple Kurs Prognose: 10 US-Dollar bis Jahresende?

Rheinmetall-, RENK-Aktien & Co. fallen: Trump könnte mit Putin wegen Ukraine-Konflikt sprechen

Ausblick: Canopy Growth stellt das Zahlenwerk zum vergangenen Quartal vor

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	08.02.2025 16:33
Kaufwert:	EUR
	Hinzufügen Speichern